Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.
about
Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumorsUltrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of art.Promising oncolytic agents for metastatic breast cancer treatmentSPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131IStructure of Reovirus σ1 in Complex with Its Receptor Junctional Adhesion Molecule-AModification of mammalian reoviruses for use as oncolytic agentsActivation of an antiviral response in normal but not transformed mouse cells: a new determinant of minute virus of mice oncotropismTargeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice.Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster modelRegression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68.What's the place of immunotherapy in malignant mesothelioma treatments?Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene.Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virusOncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic virusesSynergistic interaction between oncolytic viruses augments tumor killing.Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy.Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium.Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer.Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancersGene therapy progress and prospects cancer: oncolytic viruses.Enhanced susceptibility of B lymphoma cells to measles virus by Epstein-Barr virus type III latency that upregulates CD150/signaling lymphocytic activation molecule.Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.Oncolytic virotherapy for advanced liver tumours.Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.Proinflammatory response induced by Newcastle disease virus in tumor and normal cells.Novel delivery methods to achieve immunomodulation.Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer.Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.The evolving role of dendritic cells in cancer therapy.Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer.Oncolytic viruses: do they have a role in anti-cancer therapy?Oncolytic viruses in head and neck cancer: a new ray of hope in the management protocol.Imaging for infection: from visualization of inflammation to visualization of microbes.Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice.Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.Cell-type-specific innate immune response to oncolytic Newcastle disease virus.RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses.Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors.
P2860
Q24614856-F36FF03E-0562-4738-BD99-F8B03803B0D5Q26827216-89E18C32-3243-4AAE-B88E-9703521B8C91Q26830620-2C17E543-3F21-418A-9932-7371E1593229Q27307734-4C549E07-25DB-4E39-830F-99F7B7B48AD6Q27653146-D1F2D862-4A8C-468B-B72A-D8FEB39E1393Q28264900-6739E7B4-AC3A-459A-9A56-7C1A105674D8Q33558702-5479A82E-EC4E-4D09-B9E7-5784CC29ECD0Q33584637-BB58FFAD-8C81-40A2-83B9-7F31DF85F92FQ33713048-61425574-3BD6-40A7-89B4-A47CAC30D20EQ33772011-3F192A0D-6CFB-4C35-9712-F59CA46B79A4Q33781142-19CD0BB4-A95A-4AAE-BC5E-D6CBC8F3A505Q33815701-A77B324E-3038-42CD-8829-87CDD1FFB78CQ33887850-42F49F43-F830-4C2D-AA4D-5DA9B30BE726Q33895494-4CE851A0-3641-4915-B97D-D95FB44B6CD2Q33924550-5F9CD3A4-9B5D-4A1F-8020-7F5117919AEBQ33931616-4EB0E6E8-E9F4-4DD7-9EB4-8296C7F6CDF1Q34046125-DA208AC1-8A14-4645-A380-C3A87138F16CQ34348199-F2188C3B-1E10-495B-B887-F43837C7B0F9Q34512446-6C07F40E-6E99-41AA-B4E8-ECBCB1B3C7C2Q34707959-2C9FDB5E-FA82-4AE2-B7E0-32FC3FAADE92Q34770611-7F55B11C-D2B6-4D11-9229-BF570A4B6F35Q35051487-C44202AA-9051-4B73-9798-C426A653DFB8Q35699080-F38B32B7-DC8A-47FD-981D-7A7737F6E05DQ35832074-C845617F-6196-42B4-AF4F-8C78D9EEABEDQ36049446-52252A4F-40C6-4B57-B002-DFF17B99CF38Q36308045-6E9BFD4D-11A1-4778-847B-1B6284E41907Q36870418-EC449C12-7A4B-47C4-88AE-610BA55526CDQ36922264-46A20D18-9E20-499A-8FB4-A9A66B0F9C9CQ37582184-21F0FCBC-9DB1-49DC-B647-3C4685B7E3B8Q37687418-319A665A-7E5E-435D-A222-727B68BC53ADQ37866781-44BD1779-F919-406F-91AE-C19262F7FF4DQ37926486-1B9F0D71-6F96-4353-8BE2-8BA7A6CEBEBAQ38264443-78D536CF-7B7A-4A97-8DBB-6087BCACB7BCQ38268761-7EE5D39B-D64F-4CEC-87DA-25FBA67C884DQ38450392-224EB38A-C946-427B-ADD6-C353E7CAD56FQ38741265-EDE4022C-0870-49B9-A973-DF6CF2C2DEA5Q38962764-81F387AC-5C06-4DFA-8EEC-1D28A947B79AQ39312501-81F41262-A2DB-4035-961C-82B8C0B158ABQ39858149-7B9B59C1-D915-48AC-BF76-C1D50B646B86Q39957477-AF4D8E2E-5475-40A2-8136-7F9183993638
P2860
Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Systemic efficacy with oncolyt ...... concept and future directions.
@ast
Systemic efficacy with oncolyt ...... concept and future directions.
@en
type
label
Systemic efficacy with oncolyt ...... concept and future directions.
@ast
Systemic efficacy with oncolyt ...... concept and future directions.
@en
prefLabel
Systemic efficacy with oncolyt ...... concept and future directions.
@ast
Systemic efficacy with oncolyt ...... concept and future directions.
@en
P1433
P1476
Systemic efficacy with oncolyt ...... -concept and future directions
@en
P2093
David Kirn
P304
P356
10.1158/0008-5472.CAN-06-2871
P407
P577
2007-01-01T00:00:00Z